@article{e275c4bcc2f8447ea655580566f85a88,
title = "Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies",
keywords = "Bruton's tyrosine kinase inhibitor, chronic lymphocytic leukaemia, comorbidities, ibrutinib, survival outcomes",
author = "Burger, \{Jan A.\} and Paula Cramer and Barr, \{Paul M.\} and Dilhuydy, \{Marie Sarah\} and Anthony Mato and Byrd, \{John C.\} and Stephen Chang and Thorsten Graef and Tony Lin and Alessandra Tedeschi",
note = "Funding Information: This study was funded by Pharmacyclics, LLC, an AbbVie Company, Sunnyvale, California, USA, and Janssen Research and Development, Titusville, New Jersey, USA. Funding Information: We thank all the patients who participated in the studies included in this analysis and their families. Medical writing support was provided by Lauren D{\textquoteright}Angelo, PhD, and funded by Pharmacyclics LLC, an AbbVie Company.",
year = "2019",
month = jul,
doi = "10.1111/bjh.15784",
language = "English (US)",
volume = "186",
pages = "175--180",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley and Sons Inc.",
number = "1",
}